128 related articles for article (PubMed ID: 33221201)
1. Impact of the Delayed Initiation of Adjuvant Chemotherapy in the Outcome of Triple Negative Breast Cancer.
Morante Z; Ruiz R; Araujo JM; Pinto JA; Cruz-Ku G; Urrunaga-Pastor D; Namuche F; Flores C; Mantilla R; Luján MG; Fuentes H; Schwarz L; Aguilar A; Neciosup S; Gómez HL
Clin Breast Cancer; 2021 Jun; 21(3):239-246.e4. PubMed ID: 33221201
[TBL] [Abstract][Full Text] [Related]
2. Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer.
Gagliato Dde M; Gonzalez-Angulo AM; Lei X; Theriault RL; Giordano SH; Valero V; Hortobagyi GN; Chavez-Macgregor M
J Clin Oncol; 2014 Mar; 32(8):735-44. PubMed ID: 24470007
[TBL] [Abstract][Full Text] [Related]
3. Subpopulation treatment effect pattern plot analysis: a prognostic model for distant recurrence-free survival to estimate delayed adjuvant chemotherapy initiation effect in triple-negative breast cancer.
Morante Z; Ferreyra Y; Pinto JA; Valdivieso N; Castañeda C; Vidaurre T; Valencia G; Rioja P; Fuentes H; Cotrina JM; Neciosup S; Gomez HL
Front Oncol; 2023; 13():1193927. PubMed ID: 38023174
[TBL] [Abstract][Full Text] [Related]
4. Association between initiation of adjuvant chemotherapy beyond 30 days after surgery and overall survival among patients with triple-negative breast cancer.
Heeg E; Marang-van de Mheen PJ; Van Maaren MC; Schreuder K; Tollenaar RAEM; Siesling S; Bos MEMM; Vrancken Peeters MTFD
Int J Cancer; 2020 Jul; 147(1):152-159. PubMed ID: 31721193
[TBL] [Abstract][Full Text] [Related]
5. Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer.
Chavez-MacGregor M; Clarke CA; Lichtensztajn DY; Giordano SH
JAMA Oncol; 2016 Mar; 2(3):322-9. PubMed ID: 26659132
[TBL] [Abstract][Full Text] [Related]
6. Does time to adjuvant chemotherapy (TTC) affect outcomes in patients with triple-negative breast cancer?
Pomponio MK; Keele LJ; Fox KR; Clark AS; Matro JM; Shulman LN; Tchou JC
Breast Cancer Res Treat; 2019 Aug; 177(1):137-143. PubMed ID: 31119565
[TBL] [Abstract][Full Text] [Related]
7. Delayed initiation of adjuvant chemotherapy in older women with breast cancer.
Smith-Graziani D; Lei X; Giordano SH; Zhao H; Karuturi M; Chavez-MacGregor M
Cancer Med; 2020 Oct; 9(19):6961-6971. PubMed ID: 32767723
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of Site-Specific Metastases and Surgery in De Novo Stage IV Triple-Negative Breast Cancer: A Population-Based Analysis.
Gu Y; Wu G; Zou X; Huang P; Yi L
Med Sci Monit; 2020 Feb; 26():e920432. PubMed ID: 32043484
[TBL] [Abstract][Full Text] [Related]
9. Prolonged Time to Adjuvant Chemotherapy Initiation Was Associated with Worse Disease Outcome in Triple Negative Breast Cancer Patients.
Cai L; Tong Y; Zhu X; Shen K; Zhu J; Chen X
Sci Rep; 2020 Apr; 10(1):7029. PubMed ID: 32341397
[TBL] [Abstract][Full Text] [Related]
10. Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.
Leon-Ferre RA; Jonas SF; Salgado R; Loi S; de Jong V; Carter JM; Nielsen TO; Leung S; Riaz N; Chia S; Jules-Clément G; Curigliano G; Criscitiello C; Cockenpot V; Lambertini M; Suman VJ; Linderholm B; Martens JWM; van Deurzen CHM; Timmermans AM; Shimoi T; Yazaki S; Yoshida M; Kim SB; Lee HJ; Dieci MV; Bataillon G; Vincent-Salomon A; André F; Kok M; Linn SC; Goetz MP; Michiels S;
JAMA; 2024 Apr; 331(13):1135-1144. PubMed ID: 38563834
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study.
de Nonneville A; Gonçalves A; Zemmour C; Cohen M; Classe JM; Reyal F; Colombo PE; Jouve E; Giard S; Barranger E; Sabatier R; Bertucci F; Boher JM; Houvenaeghel G
Eur J Cancer; 2017 Oct; 84():34-43. PubMed ID: 28780480
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a beneficial effect of adjuvant chemotherapy in patients with stage I triple-negative breast cancer: a population-based study using the SEER 18 database.
Du ZL; Wang Y; Wang DY; Zhang L; Bian ZM; Deng Y; Xu CS; Lin DC; Xie L; Jia Y; Gao JD; Zhang BL
Breast Cancer Res Treat; 2020 Sep; 183(2):429-438. PubMed ID: 32647940
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of delaying initiation of adjuvant chemotherapy in patients with early triple negative breast cancer.
Hatzipanagiotou ME; Pigerl M; Gerken M; Räpple S; Zeltner V; Hetterich M; Ugocsai P; Inwald EC; Klinkhammer-Schalke M; Ortmann O; Seitz S
Breast Cancer Res Treat; 2024 Apr; 204(3):607-615. PubMed ID: 38238552
[TBL] [Abstract][Full Text] [Related]
14. Survival according to the site of metastasis in triple-negative breast cancer patients: The Peruvian experience.
Piedra-Delgado L; Chambergo-Michilot D; Morante Z; Fairen C; Jerves-Coello F; Luque-Benavides R; Casas F; Bustamante E; Razuri-Bustamante C; Torres-Roman JS; Fuentes H; Gomez H; Narvaez-Rojas A; De la Cruz-Ku G; Araujo J
PLoS One; 2024; 19(2):e0293833. PubMed ID: 38300959
[TBL] [Abstract][Full Text] [Related]
15. Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer.
Ren YX; Hao S; Jin X; Ye FG; Gong Y; Jiang YZ; Shao ZM
Breast; 2019 Feb; 43():97-104. PubMed ID: 30529406
[TBL] [Abstract][Full Text] [Related]
16. Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer.
Farolfi A; Scarpi E; Rocca A; Mangia A; Biglia N; Gianni L; Tienghi A; Valerio MR; Gasparini G; Amaducci L; Faedi M; Baldini E; Rubagotti A; Maltoni R; Paradiso A; Amadori D
Eur J Cancer; 2015 Sep; 51(14):1874-81. PubMed ID: 26206258
[TBL] [Abstract][Full Text] [Related]
17. Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.
Leon-Ferre RA; Polley MY; Liu H; Gilbert JA; Cafourek V; Hillman DW; Elkhanany A; Akinhanmi M; Lilyquist J; Thomas A; Negron V; Boughey JC; Liu MC; Ingle JN; Kalari KR; Couch FJ; Visscher DW; Goetz MP
Breast Cancer Res Treat; 2018 Jan; 167(1):89-99. PubMed ID: 28913760
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Adjuvant Treatments for T1 N0 M0 Triple-Negative Breast Cancer.
Zhai Z; Zheng Y; Yao J; Liu Y; Ruan J; Deng Y; Zhou L; Zhao P; Yang S; Hu J; We B; Wu Y; Zhang D; Kang H; Dai Z
JAMA Netw Open; 2020 Nov; 3(11):e2021881. PubMed ID: 33211105
[TBL] [Abstract][Full Text] [Related]
19. Clinical activity of adjuvant cytokine-induced killer cell immunotherapy in patients with post-mastectomy triple-negative breast cancer.
Pan K; Guan XX; Li YQ; Zhao JJ; Li JJ; Qiu HJ; Weng DS; Wang QJ; Liu Q; Huang LX; He J; Chen SP; Ke ML; Zeng YX; Xia JC
Clin Cancer Res; 2014 Jun; 20(11):3003-11. PubMed ID: 24668644
[TBL] [Abstract][Full Text] [Related]
20. Active behavior of triple-negative breast cancer with adipose tissue invasion: a single center and retrospective review.
Yamaguchi J; Moriuchi H; Ueda T; Kawashita Y; Hazeyama T; Tateishi M; Aoki S; Uchihashi K; Nakamura M
BMC Cancer; 2021 Apr; 21(1):434. PubMed ID: 33879104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
